Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?
MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.
Zacks Investment Research9/8/2026Neutral
MRK
Merck & Company IncNYSEHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$370.89B
P/E Ratio
120.26
EPS
$1.25
Beta
0.23
52W High
$156.92
52W Low
$75.81
50-Day MA
$134.59
200-Day MA
$118.40
Dividend Yield
2.18%
Profit Margin
4.77%
Forward P/E
15.72
PEG Ratio
2.97
About Merck & Company Inc
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Fundamentals
| Revenue (TTM) | $66.57B |
| Gross Profit (TTM) | $50.53B |
| EBITDA | $28.87B |
| Operating Margin | -0.24% |
| Return on Equity | 6.96% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $26.85 |
| Book Value | $16.99 |
| Price-to-Book | 8.96 |
| Price-to-Sales (TTM) | 5.57 |
| EV/Revenue | 6.35 |
| EV/EBITDA | 29.34 |
| Quarterly Earnings Growth (YoY) | -19.30% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $2.47B |
| Float | $2.46B |
| % Insiders | 0.06% |
| % Institutions | 82.74% |
Historical Volatility
HV 10-Day
29.91%
HV 20-Day
49.15%
HV 30-Day
41.06%
HV 60-Day
36.46%
HV Rank
98.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($149.50 target)
5
Strong Buy15
Buy8
HoldLatest News
Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.
Business Wire9/8/2026Neutral
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/3/2026Positive
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference.
Business Wire9/2/2026Neutral
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks Investment Research9/1/2026Positive
Merck Stock Hits New 52-Week High: What's Driving the Rally?
MRK hits a 52-week high as positive melanoma data, pipeline progress, new launches and M&A bolster its long-term growth outlook.
Zacks Investment Research8/26/2026Positive
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September is unusual for a mega-cap pharma.
24/7 Wall Street8/25/2026Positive
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
Reuters8/25/2026Neutral
“Give Me Anything But Tech”: Jim Cramer's Bold Call on the Market's Next Big Rotation
On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that carried the market for most of the past year.
24/7 Wall Street8/25/2026Neutral
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
24/7 Wall Street8/25/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/8/2026